Blue Note Therapeutics and University of California Los Angeles Jonsson Comprehensive Cancer Center Commence a Single-Arm Open-Label Phase 2 Study for BNT001
Blue Note partners with UCLA as company's first PDT candidate enters Phase 2 clinical trials.
Blue Note Therapeutics Raises $26.25 Million in Series A Financing
Company announces closing of Series A financing to scale the organization and support lead candidate, BNT001.
Cancer-related distress, which can be defined as any unpleasant feeling, emotion, or experience that affects a cancer patient’s quality of life or ability to cope with cancer diagnosis and treatment, affects millions of people. Fewer than half of those who experience cancer-related distress have access to the mental health care they need to find relief. Blue Note Therapeutics is working to close this gap.Learn more